Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inebilizumab phase 3 study in IgG4-related disease
NL-OMON58891Phase 3Completed
- Sponsor
- Horizon Therapeutics
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in IgG4-related disease (IgG4-RD) comparing Inebilizumab with Placebo (2 arms). Primary endpoint: Time to disease flare. Started Jul 2021; status: completed.
02
Drugs
inebilizumab
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on NL-OMON58891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58891.